CILADOPA

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H26N2O4
Molecular Weight	370.4421
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1OC)[C@H](O)CN2CCN(CC2)C3=CC=CC=CC3=O

InChI

InChIKey=SGEKLKJQLHJVDK-LJQANCHMSA-N

InChI=1S/C21H26N2O4/c1-26-20-9-8-16(14-21(20)27-2)19(25)15-22-10-12-23(13-11-22)17-6-4-3-5-7-18(17)24/h3-9,14,19,25H,10-13,15H2,1-2H3/t19-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3336454 | https://www.ncbi.nlm.nih.gov/pubmed/3435077 | https://www.ncbi.nlm.nih.gov/pubmed/3606037 | https://www.ncbi.nlm.nih.gov/pubmed/3574692

Ciladopa, is a troponylpiperazine derivative and dopamine agonist that has been shown to influence dopaminergic mechanisms in animals. Preclinical pharmacological studies have suggested that it has antiparkinsonian activity similar to that of bromocriptine but without many of the troublesome side effects. Unfortunately in some clinical trials no significant differences was found among the treatment groups and placebo.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
D(2) dopamine receptor 58 Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3774130	Agonist 2752

PubMed

Title	Date	PubMed
More on ciladopa.	1987-10	3435077

Patents

Sample Use Guides

In Vivo Use Guide

15 mg twice daily for 8 weeks

Route of Administration: Oral

Name

Type

Language

CILADOPA

Official Name

English

AY-27110 FREE BASE

Preferred Name

English

ciladopa [INN]

Common Name

English

2,4,6-CYCLOHEPTATRIEN-1-ONE, 2-(4-(2-(3,4-DIMETHOXYPHENYL)-2-HYDROXYETHYL)-1-PIPERAZINYL)-, (S)-

Systematic Name

English

(-)-(S)-2-(4-(.BETA.-HYDROXY-3,4-DIMETHOXYPHENETHYL)-1-PIPERAZINYL)-2,4,6-CYCLOHEPTATRIEN-1-ONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884